Akamis Bio
Akamis Bio is an oncolytic virus drug development company whose proprietary T-SIGn virus platform enables intravenous delivery of payload carrying oncolytic viruses.
Akamis Bio's proprietary Enadenotucirev vector system is differentiated by its high plasma stability, which enables efficient intravenous delivery of payload carrying oncolytic viruses to the cancer cells and tumour microenvironment without the need of complex intratumoural injections. The company is focused on solid tumours such as colorectal, ovarian and hepatic cancers.
